Harmony Biosciences Holdings (HRMY) - Total Assets
Based on the latest financial reports, Harmony Biosciences Holdings (HRMY) holds total assets worth $1.21 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Harmony Biosciences Holdings book value and equity for net asset value and shareholders' equity analysis.
Harmony Biosciences Holdings - Total Assets Trend (2018–2024)
This chart illustrates how Harmony Biosciences Holdings's total assets have evolved over time, based on quarterly financial data.
Harmony Biosciences Holdings - Asset Composition Analysis
Current Asset Composition (December 2024)
Harmony Biosciences Holdings's total assets of $1.21 Billion consist of 58.0% current assets and 42.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.3% |
| Accounts Receivable | $83.03 Million | 8.3% |
| Inventory | $7.20 Million | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $113.26 Million | 11.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Harmony Biosciences Holdings's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Harmony Biosciences Holdings market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harmony Biosciences Holdings's current assets represent 58.0% of total assets in 2024, a decrease from 97.1% in 2018.
- Cash Position: Cash and equivalents constituted 45.3% of total assets in 2024, down from 93.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 11.3% of total assets.
Harmony Biosciences Holdings Competitors by Total Assets
Key competitors of Harmony Biosciences Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Harmony Biosciences Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.75 | 3.24 | 1.95 |
| Quick Ratio | 3.72 | 3.20 | 1.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $615.40 Million | $361.13 Million | $128.35 Million |
Harmony Biosciences Holdings - Advanced Valuation Insights
This section examines the relationship between Harmony Biosciences Holdings's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 1.83 |
| Asset Growth Rate (YoY) | 23.1% |
| Total Assets | $999.20 Million |
| Market Capitalization | $1.83 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Harmony Biosciences Holdings's assets above their book value (1.83x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Harmony Biosciences Holdings's assets grew by 23.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Harmony Biosciences Holdings (2018–2024)
The table below shows the annual total assets of Harmony Biosciences Holdings from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $999.20 Million | +23.14% |
| 2023-12-31 | $811.45 Million | +20.42% |
| 2022-12-31 | $673.87 Million | +55.47% |
| 2021-12-31 | $433.44 Million | +1.49% |
| 2020-12-31 | $427.07 Million | +300.25% |
| 2019-12-31 | $106.70 Million | +19.51% |
| 2018-12-31 | $89.28 Million | -- |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitoli… Read more